Market revenue in 2023 | USD 673.3 million |
Market revenue in 2030 | USD 1,115.0 million |
Growth rate | 7.5% (CAGR from 2023 to 2030) |
Largest segment | Anti- inflammatories |
Fastest growing segment | Combination therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 63.58% in 2023. Horizon Databook has segmented the South Korea asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea’s asthma therapeutics market is expected to witness significant growth over the forecast period due to increasing healthcare expenditure, favorable government initiatives, and the growing prevalence of lung diseases. Research indicates that asthma prevalence in Korea has been on the rise, ranging from 1.6% to 4.1% in adults and 5.7% to 28.8% in children, with a gradual annual increase.
This increasing prevalence is improving the burden on medical resources. Notably, in Korean adults aged 19 to 39 years, asthma prevalence increased from 0.67% to 3.4% between 1998 and 2019 in the prepandemic period.
However, a significant decrease occurred during the pandemic (β, −0.70 [95% CI, −1.32 to −0.09]). Conversely, in Korean adults aged 40 to 49 years, there were no significant changes in asthma prevalence from 1998 to 2021.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into South Korea asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account